N/A N=91 Intensive Insulin Treatment and Ischemic Foot Ulcer
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
N/A N=12 A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
Diabetic Foot Ulcer · Peripheral Arterial Disease · Wound; Foot
Primary: Transcutaneous Oxygen Pressure (TcPO2) — 50.96 mmHg
Phase 3 N=276 Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
Diabetic Foot Ulcer
Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing — 68; 31; 23; 14 participants
N/A N=34 Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD
PVD · Arterial Ulcers
Primary: Mean Percent Reduction in Wound Surface Area — 72; 58 Percent reduction in wound surface area — p=0.086
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
N/A N=24 Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers
Diabetic Foot Ulcer · Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) at 12-week Session — 8.0; 7.0 percentage of HbA1c — p=.26
Phase 2 N=140 Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence
Venous Hypertension Ulcers · Venous Stasis Ulcer · Venous Ulcer
Primary: Number of Participants With Ulcer Recurrence — 6; 3; 11; 5 participants — p=0.091
Phase 4 N=82 Study of Oasis Ultra in Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wounds Closed — 54; 32 percentage of wounds closed
Phase 2 N=80 Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers
Diabetic Foot Ulcer · Amputation
Primary: Number of Participants With Limb Salvage — 37; 31 Participants
N/A N=381 Therapeutic Stockings to Prevent Foot Ulcers
Diabetes
Primary: Number of Participants Who Developed Foot Ulcer During Study Time Frame — 76; 82 Participants
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=20 Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology
Diabetic Foot Ulcer
Primary: Adherence to Use of SmartMat — 6.4 number of foot scans/week
N/A N=20 CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
Phase 3 N=62 The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
Diabetic Foot Ulcer
Primary: Number of All Hemorrhages — 3 Hemorrhages
N/A N=27 Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer
Diabetic Foot Ulcer · Diabetic Foot
Primary: Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking — 0.758; 0.272 Absolute change in temperature degrees
N/A N=53 MIRODERM H2H DFU Study
Diabetic Foot Ulcer
Primary: Percentage of Participants — 57.89 Percentage of participants with healed u
N/A N=131 Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers
Diabetic Foot · Diabetic Ulcer of Left Foot · Diabetic Ulcer of Right Foot
Primary: Proportion of Patients Receiving Guideline-concordant Vascular and Infectious Disease Care Processes — 14; 6 Participants
Phase 3 N=48 Beta Adrenergic Antagonist for the Healing of Chronic DFU
Chronic Diabetic Foot Ulcers · Diabetic Neuropathic Ulcers · Non Healing Wound
Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
N/A N=545 A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers
Neuropathic Diabetic Ulcer - Foot
Primary: Incidence of Complete Wound Closure — 79; 49 participants
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
N/A N=24 Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Diabetic Foot · Wound
Primary: Wound Volume — 1.16 cm^3
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84